The stock price of Quidel Corporation (NASDAQ: QDEL), a clinical genetic testing company, has seen a 10% drop in just five trading sessions. The decline was driven primarily due to the company’s preliminary report for Q1 with sales estimated to be between $374 million to $376 million, which is well short of consensus estimates of $466 million.
Full Answer
What happened to Quidel Corporation (QDEL) stock?
Mar 10, 2021 · Based on how sharply the stock fell, it seems investors are focusing on the more pessimistic way to take this. For the year, Quidel management expects revenue of $2.48 billion as a …
Why did Quidel's sales slump year-over-year?
Aug 06, 2021 · What happened. There are earnings misses, and there are earnings misses. Quidel 's ( QDEL -4.26%) latest quarter fell firmly into the latter category, and as a result its stock was tumbling by 13% ...
Why buy Thermo Fisher Scientific (TMO) and Quidel (QDEL)?
Apr 24, 2022 · americanbankingnews.com - May 9 at 9:03 AM. Quidel (NASDAQ:QDEL) Stock Rating Lowered by StockNews.com. americanbankingnews.com - May 7 at 2:16 AM. Raymond James Maintains Strong Buy on Quidel, Raises Price Target to $136 - Benzinga - Benzinga. benzinga.com - May 7 at 1:23 AM. Quidel (QDEL) Q1 Earnings, Revenues Surpass Estimates, …
What happens when a stock is oversold?
Feb 18, 2022 · Why Quidel Stock Is Popping Today By Keith Speights - Feb 18, 2022 at 11:28AM Key Points Quidel's Q4 revenue and earnings dropped sharply from the prior-year period. However, the company's results...
See more
Feb 22, 2021 · Shares of Quidel ( QDEL -0.63%) fell on Monday, continuing declines from last week. It seems the market was selling companies like Quidel that have grown revenue because of the COVID-19 pandemic....
Is Quidel Corp a good stock to buy?
Will Qdel stock go up?
The 3 analysts offering 12-month price forecasts for Quidel Corp have a median target of 136.00, with a high estimate of 219.00 and a low estimate of 125.00. The median estimate represents a +38.39% increase from the last price of 98.27.
Is Quidel a buy Stockinvest?
Who owns Quidel stock?
| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 8.07% | 3,373,746 |
| BlackRock Fund Advisors | 6.81% | 2,848,859 |
| Brown Capital Management LLC | 6.32% | 2,642,671 |
| Fred Alger Management LLC | 5.32% | 2,223,343 |
Who is invested in Quidel?
Who bought Ortho Clinical Diagnostics?
The company's Q2 headline numbers were nowhere near analyst estimates
Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles.
What happened
There are earnings misses, and there are earnings misses. Quidel 's ( NASDAQ:QDEL) latest quarter fell firmly into the latter category, and as a result its stock was tumbling by 13% in midafternoon trading on Friday.
So what
Quidel, a veteran healthcare diagnostics specialist that is known these days for its COVID-19 testing kits, reported its second-quarter results after hours on Thursday.
Now what
During the quarter, many believed we had finally turned the corner with the pandemic, so it's little wonder that COVID testing fell dramatically. With the rise of the delta variant, that trend is already very much in reverse, and Quidel's current quarter should be better.
Quidel Media Sentiment
Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.
Media Coverage
We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.
Quidel (NASDAQ QDEL) News Headlines Today
Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm.
Investors are starting to get worried now that COVID-19 is possibly declining
After spending more than a decade travelling the world exploring different cultures and languages, I'm happy to now be contributing to the Motley Fool's mission to make the world smarter, happier, and richer. What's great about exploring business and the economy is the insight it gives you into how things are in the world.
What happened
Shares of Quidel ( NASDAQ:QDEL) fell on Monday, continuing declines from last week. It seems the market was selling companies like Quidel that have grown revenue because of the COVID-19 pandemic. That might explain why the stock fell 10% today.
So what
Quidel fell last week after reporting full-year 2020 results. Counterintuitive to the drop, the company's results were quite good. Revenue in 2020 rose to $1.66 billion, up 211% from revenue in 2019. Its rapid tests for COVID-19 obviously were in high demand for much of the year, leading to the outsize growth.
Now what
There's more to Quidel's business than COVID-19 testing. Furthermore, there is some reason to believe testing could continue well into the future. For example, some researchers are beginning to say that COVID-19 could become endemic -- in other words, it will continue to circulate and not be eradicated.
What is a Sofia Q?
(QDEL) received an amended emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sofia Q device. Sofia Q is a Fluorescent Immunoassay Analyzer (FIA) from the company’s Sofia product portfolio that provides the same accuracy in SARS Antigen testing as Sofia and Sofia 2 and delivers automated results in 15 minutes. Quidel President and CEO Douglas Bryant said, “Sofia Q is our latest powerful diagnostic instrument desig
Is Lyra recalled?
Quidel Corporation (NASDAQ: QDEL) is recalling its Lyra COVID-19 Assay test due to a high risk of false-negative results in patients with high amounts of the virus. The FDA gave the molecular COVID-19 test emergency use authorization in March 2020.
Signals & Forecast
Mostly positive signals in the chart today. The Quidel Corporation stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Support, Risk & Stop-loss
On the downside, the stock finds support just below today's level from accumulated volume at $132.12 and $125.01. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Quidel Corporation finds support just below today's level at $132.12.
Is Quidel Corporation stock A Buy?
Quidel Corporation holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.